openPR Logo
Press release

Therapeutics Development of Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017: Complete Research and Development History

06-08-2017 03:39 PM CET | Health & Medicine

Press release from: Chronic Lymphocytic Leukemia (CLL)

Therapeutics Development of Chronic Lymphocytic Leukemia

ResearchMoz added Latest Research Report titled " Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017 " to it's Large Report database.

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1135785

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 44, 51, 1, 3, 53, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 7, 10 and 7 molecules, respectively.

Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Table of Contents

Table of Contents 2
Introduction 7
Chronic Lymphocytic Leukemia (CLL) - Overview 8
Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development 9
Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 35
Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 51
Chronic Lymphocytic Leukemia (CLL) - Drug Profiles 102
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 748
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 756
Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 758
Appendix 770

List of Tables
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2017 29
Number of Products under Development by Companies, H1 2017 31
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 32
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 33
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 34
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 35
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 36
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 37
Number of Products under Development by Universities/Institutes, H1 2017 38

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Therapeutics Development of Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017: Complete Research and Development History here

News-ID: 570271 • Views: 175

More Releases for CLL

Global Chronic Lymphocytic Leukemia (CLL) Drugs Market US$ 5.9 Billion by 2021
The global chronic lymphocytic leukemia (CLL) drugs market expected to reach US$ 5.9 billion by 2021, growing at CAGR 13.6% over the forecast period 2017-2021. Chronic lymphocytic leukemia is one of the most common forms of leukemia. American Cancer Society estimates about 20,110 new cases of chronic lymphocytic leukemia in the United States for 2017. CLL accounts for about one-quarter of the new cases of leukemia. The main treatments used
2017 Research Report on Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2
"Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2017" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. . . Description- '
Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review H1 – 2017: Ma …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2017”, provides an overview of Chronic Lymphocytic Leukemia (CLL) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Lymphocytic Leukemia (CLL). Report includes an overview of trial numbers and their average enrollment in top countries
Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review H1 – 2017: Ma …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2017”, provides an overview of Chronic Lymphocytic Leukemia (CLL) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Lymphocytic Leukemia (CLL). Report includes an overview of trial numbers and their average enrollment in top countries conducted
Relapsed Chronic Lymphocytic Leukemia (CLL) Pipeline Insight and Therapeutic Ass …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Relapsed Chronic Lymphocytic Leukemia (CLL)-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Relapsed Chronic Lymphocytic Leukemia (CLL). The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Relapsed Chronic Lymphocytic
Global CLL Therapeutics Market To Grow At A CAGR Of 19.16% During The Period 201 …
Researchmoz added Most up-to-date research on "Global Chronic Lymphocytic Leukemia market 2016-2020" to its huge collection of research reports. Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia